Clinical Trial Update: Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing biomarkers in aripiprazole and risperidone treatment for autistic disorder (BAART) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autistic Disorder

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)
• RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Autistic Disorder | Phase 4 | Status: COMPLETED | Results posted: 2018-09-26